The profitable sectors of health: biology, radiology, and hearing aids at the heart of Social Security spending

For several years, managing healthcare expenses remains central to the concerns of the government and social security. In 2025, the fields of medical biology, radiology, and hearing aids stand out particularly for their economic weight and profitability, sparking debates and concerns about the sustainability of financial flows. The health insurance agency releases a groundbreaking study highlighting a significant growth in turnover and profits in these areas, with operating margins often exceeding 15%, well above the national average. This reality raises the issue of “economic rents” that social security is forced to finance, calling for stricter regulation and a more equitable distribution of expenditures. In this context, major groups such as Bioscience, Radiology Plus, Auditech, and BioCare play a central role in restructuring the healthcare landscape, supported by technological players like MedTech Solutions and Santech. The stakes are multiple: cost control, care efficiency, territorial equity, and prevention of financial misappropriations related to concentration and financialization of actors. Throughout this article, a detailed spotlight on these lucrative sectors and proposals aimed at ensuring the system’s sustainability.

Analysis of profit margins in medical biology: an alarming growth

Medical biology represents a strategic sector of healthcare, involved in diagnosis and therapeutic monitoring of patients. Since 2018, the operational profitability of laboratories has experienced a notable increase, rising from 15% to nearly 24% in a few years. These high margins inevitably result from pricing of procedures set by social security, often above their actual cost, raising questions about the sector’s economic and social management.

Within biology, the market concentration among six main groups (Biogroup, Cerballiance, Inovie, Synlab, Eurofins, and Unilab) is a prominent phenomenon. These entities now represent over two-thirds of the total revenue, consolidating significant economic power that predominantly benefits their shareholders, including foreign investment funds. This concentration is also accompanied by an aggressive geographical expansion strategy, with a race to multiply sites, less aligned with actual demographic needs than with purely economic logic.

• 📈 Constantly rising operational profitability
• 🏢 Concentration around six major groups
• 🌍 Geographical expansion disconnected from actual needs
• 💰 Profits largely captured by foreign funds
• ⚠️ Risks related to excessive financialization of the sector

According to the report published by SécuSanté, this financialization also leads to fragility through excessive reliance on debt. Reckless investors have pushed some groups into delicate financial situations, threatening the medium-term stability of structures. Indeed, pressure from creditors, prioritizing financial return, can lead to a reduction in care quality and significant territorial imbalance.

Key Player 🏥	Market Share (%) 📊	Operational Profitability (%) 💹	Type of Shareholders	Average Monthly Physician Income (€) 💶
Biogroup	20%	24%	Foreign funds	8,400
Cerballiance	18%	23%	Institutional investors	8,200
Synlab	16%	22%	Private capital	8,500
Eurofins	10%	21%	Foreign funds	8,300
Unilab	6%	20%	Investment funds	8,100
Inovie	9%	19%	Private, even family	8,350

The need for structural reform, mentioned in several reports, notably on the PLFSS 2025, aims to better regulate these dynamics to ensure a fair allocation of resources and a homogeneous quality of care across the country. This perspective requires balancing economic efficiency with social responsibility.

Radiology: a rapidly expanding sector but with controversial profitability

The radiology sector is one of the most impacted by debates over healthcare costs and excessive profitability. With operational profitability rising from 11% to 16% in five years, this field remains attractive for both professionals and investors. Radiology Plus and Radiant Health are among the key names dominating this complex market, combining medical expertise and technological innovations.

A striking phenomenon concerns salary disparities among different specialists. According to a recent study by the Ministry of Health, the 5,000 freelance radiologists in France earn an average net monthly salary of 17,725 euros, while nuclear medicine doctors and radiation therapists exceed 23,000 and 34,000 euros respectively. These earnings reinforce the sector’s attractiveness but also call for a review of pricing grids, highlighted by the health insurance on its official platform.

• ⚖️ Constantly rising operational profitability
• 💼 Dominant presence of Radiology Plus and Radiant Health
• 💵 High remuneration exceeding the national average
• 🌆 Geographical concentration in major cities
• 🔄 Pressure to revise SécuSanté tariffs

The organization of territory in radiology shows a very uneven distribution of specialized clinics and centers, with a strong dominance in large urban areas. This imbalance poses a risk of “medical desertification” in rural and peripheral zones, exacerbating inequalities in access to care. The growth of private centers, guided more by economic strategies than real needs, reinforces this issue.

Profession 🧑‍⚕️	Workforce in France 🇫🇷	Average Net Monthly Salary (€) 💰	Main Groups 📌	Operational Profitability (%) 📈
Radiologists	5,000	17,725	Radiology Plus	16
Nuclear medicine physicians	375	23,600	Radiant Health	18
Radiation therapists	420	34,790	Radiology Plus	27

The modernization of equipment and digitization of practices by companies like MedTech Solutions contribute to this dynamic, while increasing costs. Regulatory pricing by social security, criticized for its lack of adaptability, needs to be reviewed to avoid exceeding the budget ceilings set within the framework of the PLFSS, as detailed on biologiste365.fr.

Hearing aids: a thriving market under increased surveillance

The hearing aid sector, led by companies such as Auditech and Audiologie France, shows increasing profitability, rising from 11% to 16% in recent years. This growth is primarily supported by demographic aging and increased awareness of hearing problems, amplifying demand and generating significant expenses for social security.

Several factors explain this concerning growth. A tariff often above the actual cost of devices, combined with sometimes aggressive commercial practices, fuels significant “rents” in this sector. Price segmentation, paired with reimbursement heavily subsidized by SécuSanté, is under particular scrutiny. The need for tariff reform and better regulation is explicitly expressed in available reports, notably in light of the latest Senate report.

• 🎧 Market driven by population aging
• 💰 Prices above actual costs
• 🛡️ Heavy dependence on SécuSanté reimbursements
• ⚠️ Commercial practices under surveillance
• 🔄 Call for tariff reform

The role of audiologists in the hearing care chain is strategic. However, their significant profitability calls for increased oversight by regulatory authorities to prevent excesses that could harm access equality, especially in rural or disadvantaged areas. The development of innovative technologies by companies like Biomédical Innov or Santech helps modernize the sector while complicating cost management.

Key Company 🎯	Operational Profitability (%) 🚀	Main Hearing Aid Models	Dependence on SécuSanté Reimbursements (%)	Market Outlook
Auditech	16	Premium models	85%	Stable growth linked to aging
Audiologie France	15	Standard devices	82%	Ongoing technological innovation
Biomédical Innov	14	Connected solutions	80%	Gradual upscale progression
Santech	13	Custom devices	78%	Development of rural markets

Faced with these challenges, a collective effort among institutions, professionals, and industry is necessary to balance supply and costs while ensuring optimal care quality for patients. The discussion on these themes is widely open within governmental bodies and specialized platforms such as Aide BTS Assurance.

Growing financialization: impact on care quality and equitable access

The financialization of healthcare sectors, particularly visible in medical biology and radiology, presents a major challenge for public regulation. The increasing influence of investment funds, often foreign, transforms these segments into lucrative markets sometimes at the expense of care quality and accessibility. Recent developments highlight the need to balance profitability with social missions.

This dynamic manifests as:

• 💼 Predominance of financial logic over health objectives
• 📉 Increased cost pressures leading to deep cuts
• 🌍 Unequal distribution of services across the country
• ⚠️ Fragilization of vulnerable structures under economic constraints
• 🤝 Call for coordinated recovery measures between public authorities and private actors

Financial optimization strategies, such as expanding sites or consolidating actors, move away from addressing actual needs and contribute to deepening territorial inequalities. According to a detailed Senate report available on le Quotidien du Médecin, this phenomenon risks exceeding budget ceilings and potentially causing a crisis in service provision.

Financialization Element 💸	Impact on Healthcare ⚕️	Recommended Actions 🤔
Market concentration	Reduced local supply and decreased competition	Strengthening regulation and antitrust controls
Excessive debt reliance	Financial fragility and quality loss	Strict regulation of external financing
Aggressive pricing optimization	Overconsumption and excessive spending	Revision of reimbursement scales

Regulatory and oversight measures, such as those included in the national health sector strategy, aim to curb these excesses to preserve fair, sustainable, and effective access to care, while fostering responsible innovation led by actors like BioCare or MedTech Solutions.

Territorial disparities: a challenge to healthcare equity in biology and radiology

Geographical inequalities in the distribution of laboratories and radiology clinics are a major issue highlighted in recent reports. Concentration in urban areas facilitates access for populations in large cities, while rural and peripheral zones remain underserved.

This issue can be observed based on several criteria:

• 🏙️ High density of actors in Île-de-France and major metropolises
• 🚜 Medical desertification in rural areas
• 📅 Insufficient efforts to develop infrastructure outside urban zones
• 🕒 Longer waiting times in some public hospitals
• 🔄 Concentration of equipment within private groups favoring profitable areas

Initiatives led by SécuSanté and Santech aim to invest in a better distribution of resources, including support for mobile units, telemedicine, and public-private partnerships to deploy quality diagnostics in isolated areas. These solutions are already recognized as essential levers to rebalance supply.

Geographical Area 🗺️	Number of Laboratories / Clinics 🔬	Average Access to Care (%)	Average Waiting Time (days) ⏳	Ongoing Initiatives 💡
Ile-de-France	2,500	95%	3	Modernization, teleconsultations
Major Metropolises	1,800	90%	4	Private care centers, public-private partnerships
Rural areas	400	60%	10	Mobile units, telemedicine

The need to strengthen dedicated programs for territorial balance, particularly by leveraging technological solutions offered by Santech or MedTech Solutions, is becoming a top priority. Access to care should not be a factor of discrimination based on geographic location, lest social disparities widen further.

Efforts to control expenses: measures and prospects within the framework of the PLFSS 2025

Faced with this situation, the Social Security Financing Bill (PLFSS) for 2025 marks a significant step in the attempt to rebalance expenditures. Social security foresees a goal of significant savings in the fields of medical biology and imaging, with cuts estimated at 3.9 billion euros next year and nearly 20 billion by 2030.

The priority measures include:

• ✂️ Limiting long-term sick leave
• 🔍 Strengthened fight against redundant care
• 🚨 Targeted actions against reimbursement fraud
• 📉 Reworking overestimated tariffs
• 🤝 Mandatory signing of regulated agreements without negotiation margin

This approach results in increased pressure on major players, including Bioscience, Radiology Plus, Auditech, and other groups operating in these fields. A dedicated report available on Aide BTS Assurance details the implications for professionals and patients. The reforms aim to establish a more balanced system, but resistance remains strong.

Measure ⚙️	Objective 🎯	Estimated Impact (Billion €) 💶	Main Concerns	Deadline ⏰
Limiting sick leave	Reduce abuse and costs	1.2	Biology, Radiology	2025-2027
Countering redundant care	Optimize care pathways	0.8	Biology	2025
Tariff revision	Reduce excessive margins	1.5	Radiology, Hearing aids	2025-2028
Regulated agreements	Align practices and costs	0.4	Biology	2025

The role of technologies and innovations in cost optimization

Technological advances are an essential factor in reconciling quality service and cost control. Companies such as MedTech Solutions, BioCare, and Santech innovate in the fields of diagnosis and prevention, contributing to more efficient care pathways.

Recent examples include:

• 🔬 Connected solutions for biology enabling automated and real-time monitoring
• 🖥️ Cutting-edge imaging platforms for digital radiology
• 🎧 Smart hearing devices tailored to each patient profile
• 📈 Predictive analysis to limit redundant medical procedures
• 🌐 Development of telemedicine and tele-diagnosis

This technological orientation is also a strategic lever in fighting financial misappropriations, by improving traceability and transparency of medical acts. The integration of such innovations into public policy is encouraged by strategic committees of the health sector, as explicitly reported on the Ministry of Economy’s website.

Perspectives on reform and calls for determined action

In a context where profitability in sectors such as biology, radiology, and hearing aids far exceeds the national average, the challenges of a profound reform are evident. The health insurance agency calls for dismantling these “economic rents” to ensure fair expenditure distribution and system sustainability.

The proposed pathways are based on:

• 🔍 Strengthening financial and tariff controls
• 🤝 Encouraging balanced public-private partnerships
• 🌍 Emphasizing territorial regulation to correct inequalities
• 📊 Increasing transparency on margins and profitability of actors
• 📜 New agreements strictly regulating relationships between insurers and professionals

For these issues, a call for determined action is launched at all levels of the system, whether by policymakers, economic actors, or healthcare professionals. The goal set for 2030 is clear: controlling expenses while maintaining care quality and access. This structural challenge, analyzed on sites like Challenges.fr, is now central to public debate.

FAQ – Understanding the financial issues of healthcare in 2025

• ❓ Why is medical biology particularly lucrative?
  The market concentration around a few large groups and tariffs above actual costs partly explain this high profitability.
• ❓ How does radiology influence social security expenses?
  The high demand, elevated specialist salaries, and current tariffs generate significant costs, placing this sector at the center of budget discussions.
• ❓ What are the consequences of financialization on care quality?
  Excessive financialization can lead to actor concentration, territorial inequalities, and pressure on care quality due to purely financial logic.
• ❓ What measures are planned to limit excessive spending?
  The PLFSS 2025 foresees savings through limiting long-term sick leave, fighting redundant care, combating fraud, and revising overestimated tariffs.
• ❓ What role do technologies play in managing healthcare costs?
  They enable better efficiency, reduction of redundancies, and increased traceability, thus contributing to expense control.

Source: www.challenges.fr